

ClinicalTrials.gov Protocol Registration and Results System (PRS) Receipt
Release Date: February 8, 2018

ClinicalTrials.gov ID: NCT03229993

Study Identification

Unique Protocol ID: OCT-20170723

Brief Title: OCT in Borderline Coronary Artery Lesions

Official Title: The Safety and Efficacy of OCT in the Evaluation and Treatment of Angiographically Borderline Coronary Artery Lesions

Secondary IDs:

Study Status

Record Verification: July 2017

Overall Status: Recruiting

Study Start: December 31, 2017 [Actual]

Primary Completion: January 31, 2018 [Actual]

Study Completion: December 31, 2018 [Anticipated]

Sponsor/Collaborators

Sponsor: The First Affiliated Hospital with Nanjing Medical University

Responsible Party: Sponsor

Collaborators:

Oversight

U.S. FDA-regulated Drug: No

U.S. FDA-regulated Device: No

U.S. FDA IND/IDE: No

Human Subjects Review: Board Status: Approved

Approval Number: 2017-SR-328

Board Name: Ethics committee of Jiangsu Provincial People's Hospital

Board Affiliation: the First Affiliated Hospital of Nanjing Medical University

Phone: 86 02583718836

Email:

Address:

Guangzhou Road 300, Nanjing, China

Data Monitoring:

Study Description

Brief Summary: To find out the safety and efficacy of Optical Coherence Tomography (OCT) in the evaluation and treatment of angiographically borderline coronary artery lesions in a Chinese population, and to compare the effectiveness of OCT versus SPECT in treating such subjects. All the participants included in the study will be those that are found to have borderline coronary artery lesions on coronary angiography, in whom the investigators feel that OCT will be useful to assess whether PCI will be of benefit to the treatment of the lesion pathology, or whether optimal medical therapy is the most appropriate treatment modality. Those participants who declined OCT will be offered SPECT as an alternative method to assess and treat the borderline coronary artery stenosis.

It is estimated that OCT guided "PCI or not" has a non-inferiority to SPECT's in the borderline coronary artery stenosis.

Detailed Description:

Conditions

Conditions: Optical Coherence Tomography (OCT)
Percutaneous Coronary Intervention (PCI)
Single-Photon Emission Computed Tomography (SPECT)
Coronary Angiography (CAG)
Borderline Coronary Artery Lesions

Keywords:

Study Design

Study Type: Interventional

Primary Purpose: Treatment

Study Phase: N/A

Interventional Study Model: Parallel Assignment

Number of Arms: 4

Masking: None (Open Label)

Allocation: Non-Randomized

Enrollment: 120 [Anticipated]

Arms and Interventions

Arms	Assigned Interventions
Experimental: OCT guided PCI	Diagnostic Test: OCT OCT is used to assess whether PCI will be of benefit to the treatment of the borderline coronary artery lesions
Experimental: OCT guided medicine	Diagnostic Test: OCT OCT is used to assess whether PCI will be of benefit to the treatment of the borderline coronary artery lesions
No Intervention: SPECT guided PCI	
No Intervention: SPECT guided medicine	

Outcome Measures

Primary Outcome Measure:

1. MACEs
The incidence of major adverse cardiac events (MACEs) including death, myocardial infarction, and stent thrombosis.
[Time Frame: 12 months]
2. TLR
The incidence of target lesion revascularization (TLR)
[Time Frame: 12 months]

Secondary Outcome Measure:

3. Rehospitalization
The incidence of rehospitalization due to cardiac events
[Time Frame: 12 months]
4. Recurrent angina
The incidence of recurrent angina
[Time Frame: 12 months]

Eligibility

Minimum Age:

Maximum Age:

Sex: All

Gender Based: No

Accepts Healthy Volunteers: No

Criteria: Inclusion Criteria:

- The inclusion criteria for this study will be only those participants in whom diagnostic coronary angiography revealed borderline coronary artery lesion. These participants will undergo the OCT procedure, or alternatively ECT.

Exclusion Criteria:

- Exclusion criteria will be those participants with previous cardiogenic shock, stroke, renal dysfunction, and acute or chronic total occlusion coronary lesions.

Contacts/Locations

Central Contact Person: Liansheng Wang, Doctor
Telephone: 86 25 68303125
Email: drlswang@njmu.edu.cn

Central Contact Backup: Haoyu Meng, Doctor
Telephone: 86 25 68303126
Email: haoyu_meng@163.com

Study Officials:

Locations: China, Jiangsu
First Affiliated Hospital of Nanjing Medical University

[Recruiting]

Nanjing, Jiangsu, China, 210029

Contact: Liansheng Wang, Doctor 025 68303125 drlswang@njmu.edu.cn

Contact: Haoyu Meng, Doctor 025 68303126 haoyu_meng@163.com

IPDSharing

Plan to Share IPD: Undecided

References

Citations:

Links:

Available IPD/Information: